We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





AI Software-Powered Device That Enables Ground-Breaking 20-Second COVID-19 Diagnosis Secures CE Mark Approval

By LabMedica International staff writers
Posted on 01 Apr 2021
An AI software-powered device that enables a ground-breaking 20-second COVID-19 diagnosis, has received the Conformité Européene (CE-European Conformity) Mark approval.

Newsight Imaging Ltd. More...
(Ness Ziona, Israel) has received CE marking for its SpectraLIT device, powered by Virusight Diagnostic Ltd.’s (Ramat Gan, Israel) AI software. The SpectraLIT device is a miniature spectrometer with advanced capabilities, operated by AI classification algorithms and developed by Virusight, Newsight’s joint venture with Sheba Medical Center’s ARC Innovation Center (Tel HaShomer, Israel). The testing procedure is easy to operate, with immediate results for symptomatic and asymptomatic patients. The AI software was successfully clinically tested by a US medical institute. Currently, the solution could be used in labs with trained operators, and the testing is done using nasopharyngeal swabs tests. However, the company intends to offer this solution for any point-of-care or even for at-home testing.

“We are very excited to achieve this important milestone for our SpectraLIT Solution, which, with Virusight’s AI, is actually a diagnosis platform for many potential cases of pathogen diagnosis, able to change the way the world deals with pandemics,” said Eli Assoolin, CEO of Newsight Imaging and Virusight Diagnostic Chairman. “We are engaged in an intensive effort to achieve more worldwide regulation approvals and to re-validate our solution in over 36 pilot programs around the globe, on all 5 continents. We are looking forward to expanding the system capabilities to diagnose other pathogens while running full commercial deployment with carefully selected partners.”

“The CE approval marks another step in the commercialization of the Virusight COVID-19 quick diagnostic kit,” added Prof. Eyal Zimlichman, Chief Medical and Innovation Officer at Sheba Medical Center and board member at Virusight. “With the realization that with the global roll out of vaccination efforts, COVID-19 will become a new reality that will require agile diagnostic solutions, this represents an important milestone. We will continuously work with our partner, Newsight, to bring about such solutions. Sheba Medical Center and ARC, our global innovation program, will continue to push the limits of innovation and impact the future of health.”

Related Links:
Virusight Diagnostic Ltd.
Newsight Imaging Ltd.
Sheba Medical Center



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Portable Electronic Pipette
Mini 96
New
Hemodynamic System Monitor
OptoMonitor
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Ultrasensitive NeXT Personal Test detects the earliest molecular signs of recurrence in breast cancer patients (Photo courtesy of Personalis)

Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients

HR+ (hormone receptor-positive) HER2- (human epidermal growth factor receptor 2-negative) breast cancer represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.